Ferriprox Twice-a-day

  • Miscellaneous hematological agents

Ferriprox Twice-a-day Generic Name & Formulations

General Description

Deferiprone 1000mg; scored tabs.

Pharmacological Class

Iron chelating agent.

How Supplied

Tabs 500mg—100; 1000mg (three times a day)—50; 1000mg (twice a day)—50, 500; Oral soln 80mg/mL—250mL, 500mL; 100mg/mL—500mL


Generic Availability


Ferriprox Twice-a-day Indications


Transfusional iron overload due to thalassemia syndromes, sickle cell disease or other anemias.

Limitations of Use

The safety and efficacy for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or with Diamond Blackfan anemia have not been established.

Ferriprox Twice-a-day Dosage and Administration

Adults and Children

<8yrs: not established. Take with food. Individualize. Round dose to the nearest half-tab (500mg). ≥8yrs: Initially 75mg/kg/day in 2 divided doses (approx. 12hrs apart). Adjust dose to individual response and therapeutic goals; max 99mg/kg/day in 2 divided doses (approx. 12hrs apart). Consider temporary dose interruption if serum ferritin falls consistently <500mcg/L.

Ferriprox Twice-a-day Contraindications

Not Applicable

Ferriprox Twice-a-day Boxed Warnings

Boxed Warning

Agranulocytosis and neutropenia.

Ferriprox Twice-a-day Warnings/Precautions


Risk of neutropenia or fatal agranulocytosis. Measure ANC before starting therapy and monitor weekly during. Interrupt therapy if infection or neutropenia develops (ANC <1.5×109/L). If neutropenia occurs, obtain CBCs, WBCs, ANC, and platelets daily until recovery (ANC ≥1.5×109/L). Monitor serum ALT monthly; consider interruption if persistent increase in transaminase levels. Monitor serum ferritin every 2–3 months. Monitor plasma zinc and supplement if deficient. Embryo-fetal toxicity. Advise to use effective contraception during and for ≥6 months (females of reproductive potential) or ≥3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for ≥2 weeks after the last dose).

Ferriprox Twice-a-day Pharmacokinetics

See Literature

Ferriprox Twice-a-day Interactions


Avoid concomitant other drugs associated with neutropenia or agranulocytosis; if unavoidable, closely monitor ANC. Avoid concomitant UGT1A6 inhibitors (eg, diclofenac, probenecid, milk thistle). Allow ≥4-hour interval with antacids or mineral supplements containing polyvalent cations (eg, iron, aluminum, zinc).

Ferriprox Twice-a-day Adverse Reactions

Adverse Reactions

Nausea, vomiting, abdominal pain, increased ALT/AST, arthralgia, neutropenia, chromaturia, pyrexia, bone pain, headache, pain in extremity, sickle cell anemia with crisis, back pain, oropharyngeal pain, nasopharyngitis, cough; agranulocytosis (manage appropriately if occurs; do not resume).

Ferriprox Twice-a-day Clinical Trials

See Literature

Ferriprox Twice-a-day Note

Not Applicable

Ferriprox Twice-a-day Patient Counseling

See Literature